Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters

ACS Nano

Volumn 8, Issue 3, 2014, Pages 2183-2195

  Cohen, Keren ^a   Emmanuel, Rafi ^a   Kisin Finfer, Einat ^a   Shabat, Doron ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

cancer multidrug resistance; doxorubicin; hyaluronan; lipid particle nanoclusters; P gp

Indexed keywords

CELL CULTURE; CHEMOTHERAPY; NANOCLUSTERS; NANOPARTICLES; PHOSPHOLIPIDS;

DOXORUBICIN; HYALURONAN; LIPID PARTICLES; MULTIDRUG RESISTANCE; P-GP;

HYALURONIC ACID;

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; HYALURONIC ACID; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE;

ADENOCARCINOMA; ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; IC 50; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; PHYSICAL CHEMISTRY; SURFACE PROPERTY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYALURONIC ACID; INHIBITORY CONCENTRATION 50; MICE; NANOPARTICLES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PHYSICOCHEMICAL PROCESSES; SURFACE PROPERTIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897003921     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn500205b     Document Type: Article

References (56)

1. Agarwal, R.; Kaye, S. B. Ovarian Cancer: Strategies for Overcoming Resistance to Chemotherapy Nat. Rev. Cancer 2003, 3, 502-516
2. Ullah, M. F. Cancer Multidrug Resistance (MDR): A Major Impediment to Effective Chemotherapy Asian Pac. J. Cancer Prev. 2008, 9, 1-6
3. Ambudkar, S. V.; Lelong, I. H.; Zhang, J.; Cardarelli, C. O.; Gottesman, M. M.; Pastan, I. Partial Purification and Reconstitution of the Human Multidrug-Resistance Pump: Characterization of the Drug-Stimulatable ATP Hydrolysis Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8472-8476
4. Chen, C. J.; Chin, J. E.; Ueda, K.; Clark, D. P.; Pastan, I.; Gottesman, M. M.; Roninson, I. B. Internal Duplication and Homology with Bacterial Transport Proteins in the Mdr1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells Cell 1986, 47, 381-389
5. Gottesman, M. M.; Pastan, I. Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter Annu. Rev. Biochem. 1993, 62, 385-427
6. Choi, C. H. ABC Transporters as Multidrug Resistance Mechanisms and the Development of Chemosensitizers for Their Reversal Cancer Cell Int. 2005, 5, 1-13
7. Hille, S.; Rein, D. T.; Riffelmann, M.; Neumann, R.; Sartorius, J.; Pfützner, A.; Kurbacher, C. M.; Schöndorf, T.; Breidenbach, M. Anticancer Drugs Induce Mdr1 Gene Expression in Recurrent Ovarian Cancer Anticancer Drugs 2006, 17, 1041-1044
8. Hotta, T.; Tanimura, H.; Tsunoda, T.; Iwahashi, M.; Tani, M.; Noguchi, K.; Mizobata, S.; Arii, K.; Terasawa, H.; Nakamori, M. et al. P-Glycoprotein Expression and Chemosensitivity in Highly Purified Fresh Human Gastrointestinal Cancer Cells Hepatogastroenterology 1999, 46, 316-321
9. Liscovitch, M.; Ravid, D. A Case Study in Misidentification of Cancer Cell Lines: MCF-7/Adrr Cells (Re-Designated NCI/ADR-RES) Are Derived from OVCAR-8 Human Ovarian Carcinoma Cells Cancer Lett. 2007, 245, 350-352
10. Schondorf, T.; Neumann, R.; Benz, C.; Becker, M.; Riffelmann, M.; Göhring, U. J.; Sartorius, J.; von König, C. H.; Breidenbach, M.; Valter, M. M. et al. Cisplatin, Doxorubicin and Paclitaxel Induce Mdr1 Gene Transcription in Ovarian Cancer Cell Lines Recent Results Cancer Res. 2003, 161, 111-116
11. Tokunaga, Y.; Hosogi, H.; Hoppou, T.; Nakagami, M.; Tokuka, A.; Ohsumi, K. Effects of MDR1/P-Glycoprotein Expression on Prognosis in Advanced Colorectal Cancer after Surgery Oncol. Rep. 2001, 8, 815-819
12. Yu, S. T.; Chen, T. M.; Tseng, S. Y.; Chen, Y. H. Tryptanthrin Inhibits MDR1 and Reverses Doxorubicin Resistance in Breast Cancer Cells Biochem. Biophys. Res. Commun. 2007, 358, 79-84
13. Apetoh, L.; Mignot, G.; Panaretakis, T.; Kroemer, G.; Zitvogel, L. Immunogenicity of Anthracyclines: Moving towards More Personalized Medicine Trends Mol. Med. 2008, 14, 141-151
14. Dal Ben, D.; Palumbo, M.; Zagotto, G.; Capranico, G.; Moro, S. DNA Topoisomerase II Structures and Anthracycline Activity: Insights Into Ternary Complex Formation Curr. Pharm. Des. 2007, 13, 2766-2780
15. Hande, K. R. Topoisomerase II Inhibitors Cancer Chemother. Biol. Response Modif. 2003, 21, 103-125
16. Linn, S. C.; Giaccone, G. MDR1/P-Glycoprotein Expression in Colorectal Cancer Eur. J. Cancer 1995, 31, 1291-1294
17. Peer, D.; Dekel, Y.; Melikhov, D.; Margalit, R. Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse tumor models Cancer Res. 2004, 64, 7562-7569
18. Schondorf, T.; Kurbacher, C. M.; Gohring, U. J.; Benz, C.; Becker, M.; Sartorius, J.; Kolhagen, H.; Mallman, P.; Neumann, R. Induction of MDR1-Gene Expression by Antineoplastic Agents in Ovarian Cancer Cell Lines Anticancer Res. 2002, 22, 2199-2203
19. Shen, D. W.; Fojo, A.; Chin, J. E.; Roninson, I. B.; Richert, N.; Pastan, I.; Gottesman, M. M. Human Multidrug-Resistant Cell Lines: Increased Mdr1 Expression Can Precede Gene Amplification Science 1986, 232, 643-645
20. Toole, B. P.; Slomiany, M. G. Hyaluronan, CD44 and Emmprin: Partners in Cancer Cell Chemoresistance Drug Resist. Updates 2008, 11, 110-121
21. Gabizon, A. A. Liposomal Drug Carrier Systems in Cancer Chemotherapy: Current Status and Future Prospects J. Drug Target 2002, 10, 535-538
22. Peer, D.; Margalit, R. Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in Syngeneic and Human Xenograft Mouse Tumor Models Neoplasia 2004, 6, 343-353
23. Arcamone, F. Properties of Antitumor Anthracyclines and New Developments in Their Application: Cain Memorial Award Lecture Cancer Res. 1985, 45, 5995-5999
24. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev. 2004, 56, 185-229
25. Monneret, C. Recent Developments in the Field of Antitumour Anthracyclines Eur. J. Med. Chem. 2001, 36, 483-493
26. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes Cancer Res. 1994, 54, 987-992
27. Allen, T. M.; Cullis, P. R. Drug Delivery Systems: Entering the Mainstream Science 2004, 303, 1818-1822
28. Chanan-Khan, A.; Szebeni, J.; Savay, S.; Liebes, L.; Rafique, N. M.; Alving, C. R.; Muggia, F. M. Complement Activation Following First Exposure to PEGylated Liposomal Doxorubicin (Doxil): Possible Role in Hypersensitivity Reactions Ann. Oncol. 2003, 14, 1430-1437
29. Moghimi, S. M.; Hamad, I.; Andresen, T. L.; Jorgensen, K.; Szebeni, J. Methylation of the Phosphate Oxygen Moiety of Phospholipid-Methoxy(polyethylene glycol) Conjugate Prevents PEGylated Liposome-Mediated Complement Activation and Anaphylatoxin Production FASEB J. 2006, 20, 2591-2593
30. Rivkin, I.; Cohen, K.; Koffler, J.; Melikhov, D.; Peer, D.; Margalit, R. Paclitaxel-Clusters Coated with Hyaluronan as Selective Tumor-Targeted Nanovectors Biomaterials 2010, 31, 7106-7114
31. Mizrahy, S.; Peer, D. Polysaccharides as Building Blocks for Nanotherapeutics Chem. Soc. Rev. 2012, 41, 2623-2640
32. Peer, D. A Daunting Task: Manipulating Leukocyte Function with RNAi Immunol. Rev. 2013, 253, 185-197
33. Eliaz, R. E.; Nir, S.; Szoka, F. C., Jr. Interactions of Hyaluronan-Targeted Liposomes with Cultured Cells: Modeling of Binding and Endocytosis Methods Enzymol. 2004, 387, 16-33
34. Eliaz, R. E.; Szoka, F. C., Jr. Liposome-Encapsulated Doxorubicin Targeted to CD44: A Strategy To Kill CD44-Overexpressing Tumor Cells Cancer Res. 2001, 61, 2592-2601
35. Peer, D.; Margalit, R. Loading Mitomycin C Inside Long Circulating Hyaluronan Targeted Nano-liposomes Increases Its Antitumor Activity in Three Mice Tumor Models Int. J. Cancer 2004, 108, 780-789
36. Peer, D.; Park, E. J.; Morishita, Y.; Carman, C. V.; Shimaoka, M. Systemic Leukocyte-Directed SiRNA Delivery Revealing Cyclin D1 as an Anti-inflammatory Target Science 2008, 319, 627-630
37. Platt, V. M.; Szoka, F. C., Jr. Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor Mol. Pharmaceutics 2008, 5, 474-486
38. Mizrahy, S.; Raz, S. R.; Hasgaard, M.; Liu, H.; Soffer-Tsur, N.; Cohen, K.; Dvash, R.; Landsman-Milo, D.; Bremer, M. G.; Moghimi, S. M. et al. Hyaluronan-Coated Nanoparticles: The Influence of the Molecular Weight on CD44-Hyaluronan Interactions and on the Immune Response J. Controlled Release 2011, 156, 231-238
39. Couvreur, P.; Barratt, G.; Fattal, E.; Legrand, P.; Vauthier, C. Nanocapsule Technology: A Review Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 99-134
40. Araujo, F. A.; Kelmann, R. G.; Araujo, B. V.; Finatto, R. B.; Teixeira, H. F.; Koester, L. S. Development and Characterization of Parenteral Nanoemulsions Containing Thalidomide Eur. J. Pharm. Sci. 2011, 42, 238-245
41. Herran, E.; Perez-Gonzalez, R.; Igartua, M.; Pedraz, J. L.; Carro, E.; Hernandez, R. M. VEGF-Releasing Biodegradable Nanospheres Administered by Craniotomy: A Novel Therapeutic Approach in the APP/Ps1 Mouse Model of Alzheimer's Disease J. Controlled Release 2013, 170, 111-119
42. Woitiski, C. B.; Neufeld, R. J.; Ribeiro, A. J.; Veiga, F. Colloidal Carrier Integrating Biomaterials for Oral Insulin Delivery: Influence of Component Formulation on Physicochemical and Biological Parameters Acta Biomater. 2009, 5, 2475-2484
43. Goldsmith, M.; Avni, D.; Levy-Rimler, G.; Mashiach, R.; Ernst, O.; Levi, M.; Webb, B.; Meijler, M. M.; Gray, N. S.; Rosen, H. et al. A Ceramide-1-Phosphate Analogue, PCERA-1, Simultaneously Suppresses Tumour Necrosis Factor-Alpha and Induces Interleukin-10 Production in Activated Macrophages Immunology 2009, 127, 103-115
44. Kedmi, R.; Ben-Arie, N.; Peer, D. The Systemic Toxicity of Positively Charged Lipid Nanoparticles and the Role of Toll-like Receptor 4 in Immune Activation Biomaterials 2010, 31, 6867-6875
45. Bartolazzi, A.; Peach, R.; Aruffo, A.; Stamenkovic, I. Interaction between CD44 and Hyaluronate Is Directly Implicated in the Regulation of Tumor Development J. Exp. Med. 1994, 180, 53-66
46. Zeng, C.; Toole, B. P.; Kinney, S. D.; Kuo, J. W.; Stamenkovic, I. Inhibition of Tumor Growth in Vivo by Hyaluronan Oligomers Int. J. Cancer 1998, 77, 396-340
47. Elinav, E.; Peer, D. Harnessing Nanomedicine for Mucosal Theranostics: A Silver Bullet at Last? ACS Nano 2013, 7, 2883-2890
48. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in Cancer Therapy and Diagnosis Adv. Drug Delivery Rev. 2002, 54, 631-651
49. Muller, R. H.; Wallis, K. H. Surface Modification of I.V. Injectable Biodegradable Nanoparticles with Poloxamer Polymers and Poloxamine 908 Int. J. Pharm. 1993, 89, 25-31
50. Toole, B. P. Hyaluronan: From Extracellular Glue to Pericellular Cue Nat. Rev. Cancer 2004, 4, 528-539
51. Chauhan, V. P.; Stylianopoulos, T.; Martin, J. D.; Popović, Z.; Chen, O.; Kamoun, W. S.; Bawendi, M. G.; Fukumura, D.; Jain, R. K. Normalization of Tumour Blood Vessels Improves the Delivery of Nanomedicines in a Size-Dependent Manner Nat. Nanotechnol. 2012, 7, 383-388
52. Jung, M. E.; Kim, W. J. Practical Syntheses of Dyes for Difference Gel Electrophoresis Bioorg. Med. Chem. 2006, 14, 92-97
53. Delgado, A. V.; Gonzalez-Caballero, F.; Hunter, R. J.; Koopal, L. K.; Lyklema, J. Measurement and Interpretation of Electrokinetic Phenomena J. Colloid Interface Sci. 2007, 309, 194-224
54. Margalit, R.; Alon, R.; Linenberg, M.; Rubin, I.; Rosenman, T. J.; Wood, R. W. Liposomal Drug Delivery-Thermodynamic and Chemical Kinetic Considerations J. Controlled Release 1991, 17, 285-296
55. Margalit, R.; Okon, M.; Yerushalmi, N.; Avidor, E. Bioadhesive Liposomes for Topical Drug Delivery: Molecular and Cellular Studies J. Controlled Release 1992, 19, 275-288
56. Peer, D.; Margalit, R. Physicochemical Evaluation of a Stability-Driven Approach to Drug Entrapment in Regular and in Surface-Modified Liposomes Arch. Biochem. Biophys. 2000, 383, 185-190